Accéder au contenu
Merck

C-053

Carbamazepine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C15H12N2O
Numéro CAS:
Poids moléculaire :
236.27
UNSPSC Code:
41116107
NACRES:
NA.24
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

grade

certified reference material

Quality Level

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

General description

Carbamazepine is an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and neuropathic pain. Marketed under trade names including Carbatrol®, Tegretol®, Carbamaze, and Biston, carbamazepine is also used as a second line treatment for bipolar disorder and in conjunction with antipsychotic drugs for schizophrenia. Suitable uses of this Certified Spiking Solution® include as starting material for preparation of calibrators and controls in carbamazepine testing methods by GC/MS or LC/MS for clinical toxicology, pain prescription monitoring, forensic analysis, or therapeutic drug monitoring applications.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

target_organs

Eyes

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

Classe de stockage

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique